1 Article

SARS-CoV-2 Omicron variant: exploring healthcare

workers' awareness and perception of vaccine

effectiveness: a national survey during the first week

of WHO variant alert

6	Mohamad-Hani	Tomeah a.b.c*	Fadi Aliamaanad*	Shuliwooh	Alonoziae	Khalid Alhasan ^{a,b} .
()	MIOHAIHAU-HAIH	i emsan "".".	raul Allalliaali".	. Diluliweeli	A TELLEZ I ".	K Hallu A Hasan

- 7 Abdulkarim Alrabiaah a,b, Rasha Assiri f, Rolan Bassrawib, Ali Alhaboob a,b, Fatimah Alshahrani
- 8 a.e, Mohamad Alarabia, Ali Alaraji, Nasser S Alharbi, Rabih Halwanijk, Amr Jamali, Ayman
- 9 Al-Eyadhya, Naif AbdulMajeedb, Lina Alfarra, Wafa Almashdali, Fahad Al-Zamila, Mazin
- 10 Barrya,e,p, Ziad A. Memish q,r, Jaffar A. Al-Tawfiqs,t,u and Sarah Alsubaiea,b

11	College of Medicine, King Saud University, Riyadh11362, Saudi Arabia
12	b Pediatric Department, King Saud University Medical City, King Saud University,
13	Riyadh11362, Saudi Arabia
14	Prince Abdullah Ben Khaled Celiac Disease Research Chair, Department of
15	Pediatrics, Faculty of Medicine, King Saud University, Riyadh11362, Saudi Arabia
16	d. Critical Care Department, King Saud University Medical City, King Saud
17	University, Riyadh11362, Saudi Arabia
18	Department of Psychiatry, College of Medicine, King Saud University Medical City,
19	King Saud University, Riyadh11362, Saudi Arabia
20	Department of Basic Medical Sciences, College of Medicine, Princess Nourah bint
21	Abdulrahman University, Riyadh 11564, Saudi Arabia
22	Division of Infectious Diseases, Department of Internal Medicine, King Saud
23	University Medical City, King Saud University, Riyadh11362, Saudi Arabia
24	h. Department of Medicine, College of Medicine, Qassim University, Qassim51452,
25	Saudi Arabia
26	Dr. Sulaiman Al Habib Medical Group, Riyadh11643, Saudi Arabia
27	Sharjah Institute of Medical Research, University of Sharjah, Sharjah27272, United
28	Arab Emirates
29	k. Department of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah
30	27272, United Arab Emirates
31	Department of Family and Community Medicine, King Saud University Medical
32	City, Riyadh 11362, Saudi Arabia
33	m. Pediatric nephrology department, Prince Sultan Military Medical City,
34	Riyadh11159, Saudi Arabia
35	n. Department of Ob-Gyn, Dr. Abdul Rahman Al Mishari Hospital, Riyadh12241,
36	Saudi Arabia
37	Department of Ob-Gyn, Dr. Fatina Imran Medical Complex, Doha233, Qatar
38	p Division of Infectious Diseases, Faculty of Medicine, University of Ottawa K1H
39	8M5, Canada
40	4 King Saud Medical City, Ministry of Health & Alfaisal University, Riyadh11533,
41	Saudi Arabia
42	Hubert Department of Global Health, Emory University, Atlanta, Georgia30322,
43	USA
44	s. Specialty Internal Medicine and Quality Department, Johns Hopkins Aramco
45	Healthcare, Dhahra34465, Saudi Arabia
46	t. Infectious Disease Division, Department of Medicine, Indiana University School of
47	Medicine, Indianapolis, IN46202, USA
48	u Infectious Disease Division, Department of Medicine, Johns Hopkins University
49	School of Medicine, Baltimore, MD21218, USA
50	

*These authors contributed equally to this research.

^{*} Correspondence to:

53	Mohamad-Hani Temsah; mtemsah@ksu.edu.sa P.O. Box 2925 (Internal Code 34).
54	Riyadh, 11461;Saudi Arabia
55	Author emails and ORCID IDs:
56	Mohamad-Hani Temsah (MHT): PO BOX 2925, Riyadh 11461, Saudi Arabia
57	mtems ah@ksu.edu.sa (https://orcid.org/0000-0002-4389-9322)
58	Fadi Aljamaan: PO BOX 2925, Riyadh 11461, Saudi Arabia faljamaan@ksu.edu.sa
59	(https://orcid.org/0000-0001-8404-6652)
60	Shuliweeh Alenezi: PO BOX 7747, Riyadh, 13321
61	salenizi@ksu.edu.sa (https://orcid.org/0000-0002-7049-0960)
62	Khalid Alhasan: PO BOX 2925, Riyadh 11461, Saudi Arabia kalhasan@ksu.edu.sa
63	(https://orcid.org/0000-0002-4291-8536)
64	Abdulkarim Alrabiaah alrabiaah@KSU.EDU.SA
65	Rasha Assiri raassiri@pnu.edu.sa https://orcid.org/0000-0001-8946-4618
66	Rolan Bassrawi rkbassrawi@ksu.edu.sa , https://orcid.org/0000-0001-7373-1531
67	Ali Alhaboob (AAH): PO BOX 2925, Riyadh 11461, Saudi Arabia drhbooob@gmail.com
68	(https://orcid.org/0000-0003-2126-7874)
69	Fatimah Alshahrani: Falshahrani1@ksu.edu.sa https://orcid.org/0000-0002-4646-7488
70	Mohamad Alarabi : PO BOX 2925, Riyadh 11461, Saudi Arabia malarabi@ksu.edu.sa
71	(https://orcid.org/0000-0001-5439-6109)
72	Ali Alaraj (AAA): PO BOX 12471, Riyadh, Saudi Arabia al_araj@hotmail.com
73	(http://orcid.org/0000-0002-7706-2328)Naser S Alharbi nsalharbi@ksu.edu.sa
74	Rabih Halwani: rhalwani@sharjah.ac.ae
75	Amr Jamal amrjamal@ksu.edu.sa
76	Ayman AL-Eyadhy aleyadhy@ksu.edu.sa
77	Naif Abdulmajeed Dr.naifq@gmail.com
78	Lina Alfarra Lalfarra19811@gmail.com
79	Wafa almashdali Almashdali@gmail.com
80	Fahad Al-Zamil fzamil@KSU.EDU.SA
81	Mazin Barry mbarry@ksu.edu.sa (https://orcid.org/0000-0003-2274-007X)
82	Ziad Memish zmemish@yahoo.com http://orcid.org/0000-0002-5099-0714
83	Jaffar A. Al-Tawfiq jaltawfi@yahoo.com (https://orcid.org/0000-0002-5752-2235)
84	Sarah Al-Subaie salsubaie@ksu.edu.sa (ORCID ID: https://orcid.org/0000-0002-3128-5921
85	Keywords: COVID-19 vaccine; SARS-CoV-2 Omicron variant; healthcare
86	workers' perceptions; SARS-CoV-2 variants
87	
88	Abstract: Background: As the SARS-CoV2 Omicron variant spreads in several
89	countries, healthcare workers' (HCWs) perceptions and worries regarding
90	vaccine effectiveness and boosters warrant reassessment.
91	Methods: An online questionnaire among HCWs in Saudi Arabia (KSA) was
92	distributed from Dec 1st to 6th 2021 to assess their perceptions, vaccine

93

94 95

96

97

98

99

100

101 102

103

104

105 106

107

as ne advocacy to the Omicron variant, and their perception of the effectivness of infection prevention measures and vaccination to prevent its spread, their Omicron variant related worries in comparison to the other variants, and their agreement with mandatory vaccination in general for adults.

Results: Among the 1285 HCW participants , two-thirds were female, 49.8~%were nurses, 46.4% were physicians, and 50.0% worked in tertiary care hospitals. 66.9% considered vaccination to be the most effective way to prevent the spread of the Omicron variant and future variants. The respondents however perceived social distancing (78.0%), universal masking (77.8%), and avoiding unnecessary travel (71.4%) as slightly superior to vaccination to prevent the spread of SARS-CoV-2 variants. HCWs aging 55 or older agreed singficanlty with vaccine ineffictivness to control Omicron spread, while those who believed in non-pharmacolgical infection prevention measures agreed signifcantly with vaccination for that purpose. Male HCWs had a significant agreement with mandatory vaccination of all eligible adult populations. On the other hand, unwilling HCWs to receive the vaccine had strong disagreements with mandatory vaccination.

Conclusions: The current study in the first week of Omicron **showed that** only two-thirds of HCWs felt that vaccination was the best option to prevent the spread of the **Omicron** variant, indicating the need for further motivation campaigns for vaccination and booster dose. HCWs had a strong belief in **infection prevention measures to contain the spread of SARS-CoV-2 variants** that should be encouraged and augmented.

1. Introduction:

The B.1.1.529 variant of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first reported to the World Health Organization (WHO) from South Africa on November 26, 2021 [1]. This emerging variant was named Omicron and designated as a variant of concern (VOC). This variant has more than 30 mutations on its spike protein. And similar to the Alpha variant, it is associated with an S-gene target failure on a specific PCR assay due to the presence of 69-70 deletions [2]. Preliminary evidence suggests an increased risk of reinfection with this variant and high contagiousness [3,4]. The Omicron variant had been reported in 110 countries across all six WHO regions as of December 22, 2021[5]. [1,2]In addition, the B.1.1.529 variant was thought to have a higher transmissibility rate than other circulating variants [3,6,7]. More concern has arisen from the questionable whether current vaccines provide adequate protection against this variant [8]. A recent study showed a 41-fold decline of the geometric mean titer (GMT) inverse of the plasma dilution required for 50% reduction in infection (FRNT50) with Omicron compared to previous infection with the wild-type virus, with a three-fold reduction in FRNT50 with the mRNA vaccine BNT162b2[9]. However, it is likely that previous infection followed by vaccination, or a booster dose for those completing their primary series, will likely increase neutralization levels that would confer the needed protection against severe disease from the emerging Omicron variant [10]A recent study showed that even with Omicron, the rate of hospitalization was highest among unvaccinated and lowest among those who received a booster dose.88% likelihood to escape current vaccines[11-13].

As new variants emerge, HCWs must continue to serve COVID-19 and non-COVID patients while still fulfilling personal commitments for their families and themselves[14-16]. Burnout, emotional exhaustion, mental distress, depression and psychological stress have been linked to HCWs during this pandemic, and research continues to reveal high rates of infection [17]. In addition to patient care, HCWs must keep up with any developments in relation to emerging variants and their effects on clinical presentation, management, and measures of prevention—mainly vaccination and infection prevention practices[18,19]. As the Saudi Ministry of Health announced the first case of Omicron variant on Dec 1st, 2021[20], we undertook this study to assess HCWs' awareness about the SARS-CoV2 Omicron variant, their worry levels in relation to the different SARS-CoV2 variants, their perception of the effectiveness of the current vaccines, and other preventive measures to inhibit the spread of the Omicron variant or other future variants, as well as to assess their agreement with mandatory vaccination of the adult population.

2. Method

2.1 Data Collection

This was a cross-sectional survey (Appendix 1) carried out among HCWs in Saudi Arabia (KSA), conducted between Dec 1 and 6, 2021. Participants were invited via a convenience sampling technique through various healthcare providers' social media platforms, such as WhatsApp, Twitter, and emails.

HCWs were surveyed regarding their Omicron variant awareness, perceptions of the effectiveness of COVID-19 vaccinations and other measures to prevent its spread and that of other future variants, and their agreement with mandatory vaccination for all eligible adults. The last part of the survey focused on HCWs' resilience, anxiety, and coping strategies, which was published as preprint [21]. The current survey was adopted from our previously published studies, with modifications related to the new Omicron variant [22-25]. The questionnaire was pilot-validated and sent through the SurveyMonkey© electronic platform as described previously [22-25].

Participants gave consent at the beginning of the survey, were notified about the purpose of the study, and participated voluntarily in the study. The Institutional Review Board at the College of Medicine and King Saud University approved the study (approval 21/01039/IRB).

2.2 Statistical analyses

The mean and standard deviation were used to assess continuous variables (worry level for example), frequency and percentage were used for categorically measured variables (agreement with mandatory vaccination for example, age was analyzed as categories). The 5-point Likert score was analyzed by categorical method to assess agreement versus disagreement, the participants' responses were grouped into two groups: 1. Agree including agree and strongly agree responses; 2. Disagree including disagree, strongly disagree and neither agree nor disagree responses. A histogram and the K–S statistical test of normality were used to assess the statistical normality assumption of the continuous variables, and Levene's test was used to assess the homogeneity of statistical variance assumption. A multiple-response dichotomies analysis was used to analyze the multiple response variables (participants' source of information for example). Pearson's correlations test (r) was used to assess the correlations between metric variables. Multivariate binary logistic regression analysis was used. The associations were expressed as the odds ratio and 95% confidence interval. The SPSS IBM statistical analysis program (Version#21. Armonk, NY: IBM Corp.) was used for the statistical data analysis. The statistical significance level (P-value) was considered at 0.01 if achieved, and 0.05 if 0.01 not achieved according to the used software.

3. Results:

A total of 1285 HCWs completed the online survey. Table 1 shows the participants' baseline characteristics. The majority (64%) were female, and 70.9% aged between 25 and 44 years. The majority were expatriates (62.3%). Regarding their clinical role, 49.8% were nurses—and 46.4% were physicians, of whom 24% were consultants. Fifty percent worked in tertiary institutes, while two-thirds worked in the outpatient department (OPD) or general wards.

Table.1: Baseline characteristics of the participating HCWs. N=1285

Variable	Frequency	Percentage
Sex		
Female	822	64.0

Male	463	36.0
Age Group		<u>.</u>
25-34 years	434	33.8
35 to 44 years	477	37.1
45-54 years	273	21.2
≥ 55 years	101	7.9
Nationality		
Saudi	484	37.7
Expatriate	801	62.3
Clinical Role		
Consultant	319	24.8
Assistant Consultant/Fellow	74	5.8
Resident/Registrar	203	15.8
Nurse	640	49.8
Allied Health Practitioner	49	3.8
Hospital Type		
Primary Healthcare Center	338	26.3
Secondary Hospital	302	23.5
Tertiary Hospital	645	50.2
Hospital Working Area		
Intensive Care Unit (ICU)	141	11.0
Emergency Room (ER)	91	7.1
Operating Room (OR)	41	3.2
COVID-19 Isolation Ward	53	4.1
General Ward	492	38.3
Outpatient Department (OPD)	368	28.6
Non-Clinical Area	99	7.7
Geographical Region		
Riyadh City and Central Region	740	57.6
Eastern Province	71	5.5
Western Province	120	9.3
Northern Province	34	2.6
Southern Province	320	24.9

Almost all (97.9%) of the participants did not recently travel to countries where the Omicron variant has been recorded. Most (71%) HCWs had not been in contact with COVID-19 patients during the last 3 months, while 22.3% of the HCWs had developed COVID-19 previously.

Regarding COVID-19 vaccination, 99.5% had received two doses, and the first dose was divided equally between AstraZeneca ChAdOx1-S and Pfizer vaccines, and 75% of the second dose was of the Pfizer–BioNTech COVID-19 vaccine. Regarding the booster dose, 94.1% either

received or planned to receive it once eligible, according to time-based criteria of the local regulations (Table 2).

Table.2: Descriptive analysis of the HCWs' experiences of COVID-19 disease, screening and immunization.

Variable	Frequency	Percentage
Have you been in contact with COVID-19 patients during the p	oast 3 months?	
No	912	71.0
Yes	373	29.0
Were you previously diagnosed with PCR-positive COVID-19	yourself?	
No	999	77.7
Yes	286	22.3
Did you travel to any country where the Omicron variant has b month?	een recorded during the last	
Yes	27	2.1
No	1258	97.9
Which vaccine did you receive for your first COVID-19 vaccine	e shot?	
AstraZeneca ChAdOx1-S	600	46.7
Moderna	5	0.4
Pfizer–BioNTech	676	52.6
Not received	4	0.3
Which vaccine did you receive for your second COVID-19 vacc	ine shot?	
AstraZeneca ChAdOx1-S	296	23.0
Moderna	20	1.6
Pfizer–BioNTech	963	74.9
Not received	6	0.5
Did you receive the third (booster) COVID-19 vaccine?		
Yes	250	19.5
No: not yet eligible for it	566	44.0
No: I do not want to receive it	76	5.9
No: but I am planning to register for it	393	30.6

* Mean (SD)

Table 3 shows the participating HCWs' awareness and knowledge of the available literature concerning certain facts and queries related to the Omicron variant (key answers displayed in brackets). Almost all (93%) the participating HCWs knew that the Omicron variant was first described in South Africa; however, 81.7% believed that the Omicron variant was already reported in Saudi Arabia. Of the respondents, 66% knew that Omicron variant is more transmissible than the Delta variant, while 26.7% were not sure. The majority (71.8%) did not know that the Omicron variant spike protein has 22 mutations. Still, 56.2% expected that Omicron variant causes similar signs and symptoms to the original variant. Most (85.1%) of our cohort were aware that SARS-CoV-2 mutations are expected, while they were almost equally divided regarding their

opinion on whether they were unsure or whether the Omicron variant may/may not cause more severe disease compared to previous variants. About half of the participants were unsure if mRNA or vector-based vaccines are effective against the Omicron variant. At least two-thirds of them were unsure if therapeutics such as monoclonal antibodies used against previous variants might be effective against the variant.

The mean participants' self-rated familiarity with the Omicron and Delta variants of the SARS-CoV-2 virus was 3.24 (SD 0.95) and 3.5 (SD0.99), respectively, with strong and significant correlation between these scores p < 0.0001 (t = 6.7928, df = 2568). When we explored the participants' sources of information about the Omicron variant, the MOH and WHO websites were the main sources, but social networks were also used to obtain information in equal measure (about 50%), followed by Official statements (41%), hospital announcements (38%), and the Center of Disease Control (CDC) and Saudi CDC websites, which were accessed almost equally (between 30 and 33%), while scientific journals were lower down on the list (28.7%).

Table 3: Descriptive analysis of HCWs' awareness and knowledge of the Omicron variant.

	True	False	Neither
Variable	No. (%)	No. (%)	True/False
			No. (%)
The Omicron variant is more	848 (66.0%)	94 (7.3)	343 (26.7)
transmissible than Delta (True)			
"Omicron" is one of the letters of the	674 (52.5)	81 (6.3)	530 (41.2)
Greek alphabet (True)			
The Omicron virus spike protein	362 (28.2)	211	712 (55.4)
has 22 mutations (True)		(16.4)	
SARS-CoV2 Omicron variant signs	722 (56.2)	292	271 (21.1)
and symptoms are the same as the		(22.7)	
original SARS-CoV-2 variant (False)			
SARS-CoV-2 virus mutations are	1094 (85.1)	23 (1.8)	168 (13.1)
expected (True)			
The Omicron variant causes more	493 (38.4)	374	418 (32.6)
severe disease than the original		(29.1)	
variant (False)			
People who have previously had	480 (37.4)	269	536 (41.7)
COVID-19 could become reinfected		(20.9)	
more easily with Omicron (True)			
COVID-19 mRNA vaccines	376 (29.3)	258	651 (50.7)
(Pfizer-BioNTech and Moderna) might		(20.1)	
be less effective against the Omicron			
variant (not confirmed in the			
literature)			
COVID-19 vector-based vaccines	290 (22.6)	233	762 (59.3)

Г	I	T		
(AstraZeneca ChAdOx1-S) might be		(18.1)		
less effective against the Omicron				
variant (not confirmed in the				
literature)				
Therapeutics such as monoclonal	251 (19.5)	154	880 (68.5)	
antibodies might be less effective		(12.0)		
against the Omicron variant (not				
confirmed in the literature)				
Variable	Frequency		Percentage	
To the best of your knowledge, wl	here was the SARS	5-CoV-2 O	micron variant first	
identified?				
UK	15		1.2	
USA	16		1.2	
South Africa	1197		93.2	
China	47		3.7	
India	10	0.8		
Participants' self-rated familiarity v	with the Omicron		3.24 (0.95)	
variant *				
Participants' self-rated familiarity	with the Delta		3.50 (0.99)	
variant *				
Participants' sources of information	about the Omicron	variant		
Hospital announcements (e.g.,	400		20.0	
roll-ups or newsletters)	488		38.0	
Official statements or press releases				
from MOH (e.g., through SMS or	527		41.0	
newspapers)				
MOH website	647	50.4		
WHO website	662	51.5		
CDC website	395	30.7		
Saudi CDC	430	33.5		
Social networks (such as YouTube,	(00		40.2	
Facebook, Twitter, WhatsApp, etc.)	633		49.3	
Scientific journals	369	28.7		
Other sources	205		16.0	
l	I	<u> </u>		

* Mean (SD)

Of the participants, 66.9% agreed with the vaccine's effectiveness to prevent the spread of Omicron or other future variants, while when considering other preventive measures, such as universal masking, social distancing, and avoiding unnecessary international travel, their agreement was higher (77.8%, 78%, and 71.4%, respectively). Participating HCWs (82.2%) felt that the COVID-19 vaccination should be mandatory for all eligible adult populations, while only 5.1% disagreed (Table 4).

Almost half (42.7%) of the HCWs perceived that any of the current mRNA vaccines (Pfizer–BioNTech COVID-19 vaccine or Moderna COVID-19 vaccine) would be the best COVID-19 booster vaccine, while 26.9% felt that a newly developed mRNA vaccine that would better target the Omicron variant is best, and 26.2% agreed to receive any of the available vaccines as a third booster dose (Table 4).

Regarding the participants' perceived risk from the Omicron variant, 16.9% felt that patients with immune deficiencies are at the highest risk, followed by the elderly (14.9%), HCWs (14.1%), and then patients with chronic medical illnesses (Table 4).

When assessing the participants' perceptions about future perspectives of the Omicron variant locally and internationally, 57.7% agreed that it has the potential to cause a new COVID-19 pandemic wave worldwide, while only 45.9% agreed that it may cause another COVID-19 wave in Saudi Arabia, and 46.1% agreed that it may cause a lockdown (Table 4). The current cohort of HCWs had the highest worry level in relation to international travel (3.19, SD 1.12), followed by the Omicron variant (2.18, SD 1.14), and their worry levels in relation to the original SARS-CoV-2 and Delta variants were comparable (1.96, SD 1.14 and 1.97 SD, 1.13, respectively), while their worry level in relation to the Alpha variant was the lowest (1.67, SD 1.1).

Table 4: Descriptive analysis of the HCWs' beliefs, attitudes, and practices concerning the SARS-CoV2 Omicron variant.

Variable	Frequency	Percentage		
Vaccines are the most effective way to prevent the spread of the Omicron variant or other future variants				
Agree	860	66.9		
Disagree	425	33.1		
Universal masking is still effective in preventing the spread of the Omio	cron variant or	other future		
Agree	999	77.8		
Disagree	286	22.2		
Social distancing is still effective in preventing the spread of the Omic variants	ron variant or	other future		
Agree	1002	78.0		
Disagree	283	22.0		
Avoiding unnecessary international travel is still effective in preventing variant or other future variants	the spread of	the Omicron		
Agree	917	71.4		
Disagree	368	28.6		
The COVID-19 vaccine should be mandatory for all adult populations				
Agree	1056	82.2		
Disagree	229	17.8		
In view of the Omicron variant outbreak, what do you think is the best boos	ter COVID-19 v	accine?		
Any of the current mRNA vaccines (Pfizer-BioNTech or Moderna	549	42.7		
COVID-19)				

variant		
Another, non-mRNA-type vaccine	53	4.1
It does not matter; I will be OK with receiving any vaccine as a third	337	26.2
booster dose		
Who is at the highest risk from the Omicron variant in your opinion?		
The elderly	894	14.9
Patients with diabetes	753	12.6
Patients with cardiovascular diseases such as hypertension	703	11.7
Patients with chronic renal disease	792	13.2
Patients with immune deficiency	1014	16.9
Healthcare workers	846	14.1
The obese population	607	10.1
The young population	335	5.6
Previously unvaccinated people (added from others)	18	0.3
Others	36	0.6
The Omicron variant has the potential to cause a new COVID-19 pandemic	wave worldv	vide.
Agree	741	57.7
Disagree	544	42.3
The Omicron variant may cause another COVID-19 wave in Saudi Arabia.		-
Agree	590	45.9
Disagree	695	54.1
A second national lockdown may be implemented if an Omicron variant out	tbreak occur	s.
Agree	593	46.2
Disagree	692	53.8
Using a Likert rating from 1-5, how worried are you by		
International travel *		3.19 (1.12)
The original variant that started the first pandemic *		1.96 (1.14)
The Alpha variant (which was first described in the UK)*		1.67 (1.1)
The Delta variant (which was first described in India)*		1.97 (1.13)
The new Omicron variant *		2.18 (1.14)

* Mean (SD)

HCWs' perceptions of vaccination and other preventive measures to prevent the spread of SARS-CoV-2 variants

The HCWs' belief in universal masking, social distancing, and avoiding unnecessary international flights to prevent the spread of SARS-CoV-2 variants correlated strongly and significantly with their belief that vaccines are still the most effective way to prevent the spread of Omicron and other future variants (r = 0.707, 0.675, 0.603, respectively; p < 0.01). Their mean worry level in relation to international travel also correlated significantly with the above measures (r = 0.707, 0.675, 0.603).

0.102, 0.134, 0.157, respectively; p <0.01), which also correlated with their agreement with COVID-19 vaccine mandates for all adults (r = 0.139, p < 0.01). Their mean worry level in relation to the Omicron variant correlated significantly and strongly with their perception of the effectiveness of the above preventive measures, including vaccination to prevent its spread and mandatory vaccination (r = 0.082, 0.103, 0.132, 0.160, 0.114, respectively; p <0.01). Self-rated familiarity with the Omicron or Delta variants correlated strongly and significantly only with their agreement of universal masking as a preventive measure to prevent the spread of other variants, including Omicron, (r = 0.090, 0.094, respectively; p <0.01). Additionally, their familiarity with either variant correlated significantly with their agreement with mandatory vaccination (r = 0.167, 0.142, respectively; p < 0.01) (Table 5).

Table 5: Correlation between participants' perceptions about vaccines, universal masking and social distancing to prevent the spread of the Omicron variant.

	Vaccines	Universal	Social	COVID-19
Variable	effectiveness	masking	distancing	vaccine
	a	effectiveness b	effectiveness ^c	mandate ^k
Universal masking d	.707**			
Social distancing	.675**	.889**		
effectiveness e				
Avoiding	.603**	.755**	.794**	
unnecessary				
international travel f				
Omicron variant	002	.011	.017	
potential/new				
COVID-19 pandemic				
g				
Omicron variant	.005	015	.000	
potential/COVID-19				
wave h				
Omicron variant	.010	.027	.051	
potential/lockdown ¹				
COVID-19 vaccine	.179**	.117**	.113**	
mandate k				
Mean worry level in	.102**	.134**	.157**	
relation to				
international travel				
Mean worry level in	.069*	.091**	.111**	.139**
relation to original				
variant				
Mean worry level in	.065*	.075**	.098**	.148**

relation to Alpha variant				
Mean in relation to level from Delta variant	.069*	.109**	.124**	.114**
Participants' mean worry level in relation to the Omicron variant	.082**	.103**	.132**	.114**
Self-rated familiarity with Omicron variant	.090**	.055*	.069*	.167**
Self-rated familiarity with the Delta variant	.094**	.062*	.066*	.142**

a Vaccines are still the most effective way to prevent the spread of Omicron and other future variants. b Universal masking is still effective in preventing variant spread. c Social distancing is still effective in preventing variant spread. d Participants' agreement level with universal masking still being effective in preventing the spread of SARS-CoV-2 variants. Participants' agreement level with the effectiveness of social distancing to prevent the spread of SARS-CoV-2 variants. Participants' agreement level with the effectiveness of avoiding unnecessary international travel to prevent the spread of SARS-CoV-2 variants. Participants' agreement level with the potential of the Omicron variant to cause a new COVID-19 pandemic wave worldwide. Participants' agreement level with the potential of the Omicron variant to cause second lockdown. Participants' agreement level with COVID-19 vaccine mandates.

**. Correlation is significant at the 0.01 level (2-tailed). * Correlation is significant at the 0.05 level (2-tailed). Note: Correlation (r) coefficients <0.10 are considered non-significant or are weak even if their p values are <0.050.

Multivariate logistic regression analysis of multi-variables related to the HCWs and their perception of the ineffectiveness of the currently available COVID-19 vaccines to prevent the spread of SARS-CoV-2 variants found that the HCWs' age correlated positively with their agreement with the ineffectiveness of the COVID-19 vaccines when they were aged over 35 years (OR = 1.25, p = 0.235), and significantly when they were aged 55 and above (OR = 1.96, p = 0.034) (Figure 1) (Table 6). HCWs who strongly believed that universal masking and avoiding unnecessary international flights are still effective ways to prevent the spread of mutant variants were in significant disagreement with the ineffectiveness of the vaccines to prevent the spread of current and future mutant variants.

In addition, those who believed that COVID-19 vaccination should be mandatory for all adults or believed that mutant variants are an expected phenomenon also showed strong disagreement with the ineffectiveness of the vaccines. HCWs who worked in critical care areas showed significant agreement with the belief that the COVID-19 vaccines are ineffective in preventing the spread of mutant variants. Regarding the HCWs' sources of information, those who significantly relied on the WHO did not believe in the efficacy of the vaccines to prevent the spread of current or future mutant variants (Table 6).




Figure 1: Odds ratio between the participants' ages and their agreement with the ineffectiveness of the COVID-19 vaccines to prevent the spread of mutant variants; the correlation is significant for those over 55 years old; p = 0.034.

Table 6: Multivariate logistic regression analysis of odds of agreement with the ineffectiveness of the COVID-19 vaccines to prevent the spread of mutant variants, especially Omicron.

	Multivariate	95% C.I. for OR		
Variable	adjusted odds	Lower	Upper	p value
	ratio			
Sex =male	.857	.609	1.208	0.379

	T	1	1	
Age =35 to 44 years	1.255	.863	1.827	0.235
Age =45-54 years	1.502	.967	2.332	0.070
Age >=55 years	1.965	1.054	3.663	0.034
Work area =ICU	1.925	1.194	3.103	0.007
Work area = OR	2.148	.878	5.255	0.094
Previously diagnosed with COVID-19	1.292	.897	1.863	0.169
Does not want to take the COVID-19 vaccine	1.564	.833	2.937	0.164
Believes SARS-CoV-2 variants are expected	.799	.638	1.000	0.050
Believes universal masking is still effective at preventing the spread of variants	.318	.258	.393	<0.001
Believes avoiding unnecessary international travel is still effective at preventing the spread of variants	.617	.499	.763	<0.001
Agreement level that the Omicron variant has the potential to cause a new COVID-19 pandemic wave worldwide	1.208	.934	1.562	0.149
Agreement level that COVID-19 vaccination should be mandatory for all adults	.355	.263	.478	<0.001
Source of info: MOH website	.760	.544	1.062	0.108
Source of info: WHO website	1.474	1.046	2.077	0.027
Source of info: CDC website	.768	.521	1.133	0.183
Source of info: Scientific journals	.774	.526	1.137	0.191
Worry level in relation to the Delta variant	1.127	.971	1.307	0.117

Dependent variable: COVID-19 vaccine ineffectiveness to prevent the spread of mutant variants, especially Omicron.

An analysis of the characteristics of the surveyed HCWs found that males (compared to females) were in significant agreement with mandatory vaccination of all eligible adults, while age did not correlate with agreement with mandatory vaccination. HCWs who relied on social media as a source of information were in significant agreement with mandatory vaccination for all adults, self-rated familiarity level with the Omicron variant and the agreement that there could be further national lockdowns due to the Omicron variant. Furthermore, the level of agreement with the effectiveness of vaccines to prevent the spread of mutant variants correlated significantly with agreement with mandatory vaccination.

Those who were absolutely unwilling to receive the vaccine were five times more likely to disagree with mandatory vaccination, while those who agreed with the effectiveness of unnecessary travel avoidance to prevent the spread of mutant variants were 1.5 times more likely to disagree with the mandatory vaccination of all eligible adults (Table 7).

Table 7: Multivariate logistic regression analysis of odds of disagreement with mandatory COVID-19 vaccination.

Variable	Multivariate adjusted odds ratio	95% C.I. for OR		p value
		Lower	Upper	
Sex = male	.692	.487	.983	.040
Age group	.865	.723	1.035	.113
Nationality = expatriate	.295	.209	.416	<0.001
Absolute unwillingness to receive vaccines	5.661	3.303	9.704	<0.001
Reliance on social media as source of information	.614	.438	.860	.005
Reliance on MOH official statements as source of information	1.278	.914	1.788	.152
Self-rated familiarity level with Omicron variant	.754	.637	.893	.001
Agreement level with the effectiveness of vaccines to prevent the spread of variants	.525	.428	.644	<0.001
Agreement level with the effectiveness of unnecessary travel avoidance to prevent the spread of	1.438	1.188	1.740	<0.001

variants			
Agreement level with the	.472	.714	<0.001
possibility of a second national lockdown due to the Omicron			
variant			

Dependent variable: disagreement with mandatory COVID-19 vaccination.

314 315

316

317

318

319

320

321

322

323 324

325

326

327

328

329

330

331

332

333

334 335

336

337

338

339 340

341

342343

Discussion

This study explored HCWs' perceptions and awareness of the SARS-CoV-2 Omicron variant after the initial WHO alert, in addition to their agreement with vaccine effectiveness to prevent its spread or other potential future variants. Most (64%) respondents were female, similar to a previous study about Delta variant concerns in KSA. This was also in agreement with other studies showing that the majority of HCWs are female [25-27].

One-fifth of study participants received a booster dose, while the majority reported plans to receive it once they became eligible, with a small percentage (6%) not planning to receive it. The majority (69.6%) in our study chose to receive the booster dose with any of the currently available mRNA vaccines or newly developed ones; this observation mirrors another study conducted in a neighboring country among HCWs, where they also preferred mRNA vaccines[28]. Such behavior could be partly due to the hematological side effects that have been recorded with the viral vector vaccines [28]. In addition, this could signal vaccine selectivity (VS), which is currently an emerging public health challenge due to the multiplicity of vaccine options. Another explanation is vaccine hesitancy (VH), which could be related to reliance on social media as the main source of information, which was reported by almost half of the participants, as opposed to less than one-third who reported utilizing scientific journals as a main source of information; therefore, increased access to peer-reviewed journals should be strongly encouraged among HCWs[25]. Keeping in mind the double edge sword effects the social media plays on individuals' decision making, as social media spreads information that's not scientifically always verified, puts their personal touch or psycho-cognitive flavor that drives the audience, therefore our observation of social media being highly used source of information by the surveyed HCWs can explain some observations like (VS), (VH) and HCWs significant agreement with mandatory vaccination for all adults. Such agreement might be a reflection of their self-rated familiarity level with the Omicron variant (stemming from the information they acquired from social media) that also correlated significantly with their agreement with mandatory vaccination. Social media spread with the emergence of the Omicron variant a huge load of information that was potentially driving all sectors of the society to abide with all the measures of protection including vaccination, from SARS-CoV-2 including its new Omicron variant.

The primary concerns regarding Omicron are whether it is more contagious, more virulent, or both, in comparison to other variants, and how likely it would be to evade natural (post previous COVID-19 infection) and vaccine-induced immunity [11,29-31]. However, with more than 30 mutations and some deletions that are similar to other variants, increased transmissibility and higher antibody escape were expected [32]. However, with few clinical and epidemiological data to help define the true threat of Omicron, participants' mixed knowledge responses are expected, as has been observed in our study, in which they even extended to their belief in the effectiveness of the vaccines to control its spread [33]

Among our study participants, regarding the perceived effectiveness of various methods to control the spread of the Omicron variant, social distancing and universal masking scored the highest, followed by avoiding international flights and, lastly, vaccination. Again, such observations shed light on their questioning of the vaccine's effectiveness against Omicron due to its many mutations, especially involving the spike protein. Their perceived effectiveness of the current COVID-19 vaccines against the Omicron variant was 67%. This represents a decline in HCWs' perception of vaccine efficacy compared to our earlier study, performed in December 2020 during the initial rollout of the COVID-19 vaccines, which was 80.2% [34]. Such findings reflect declining confidence in vaccine efficacy against emerging variants, which is noteworthy since their concerns about efficacy have been stated as one of the main reasons for vaccine hesitancy [35]. COVID-19 vaccine-related uncertainty and challenges persist in the face of combacting emerging SARS-CoV-2 variants. Immune escape is a real concern with the Omicron variant. According to findings from South Africa, the efficacy of the Pfizer-BioNTech vaccine against the Omicron variant was significantly reduced, with a 41-fold lower level of neutralizing antibodies when compared to the wild-type variant of SARS-CoV-2 [10].

> The fact that 82.2% of HCWs agree with mandatory COVID-19 vaccination for all adults is an interesting finding. Mandating immunizations for HCWs or other business employees is not only ethical, but also legal. Employers have the right to require vaccination as a condition of employment, as the Equal Employment Opportunity Commission and courts have stated [36] and a multi-society statement on COVID-19 vaccination had been also released[37]. This right applies to both vaccinations approved for emergency use and those that have been fully approved by the FDA. Mandates, however, can erode public support, causing a backlash and even lowering vaccine uptake. There are no established processes to enforce population-wide vaccination obligations in most countries, despite the fact that employers, healthcare providers, and educational institutions can monitor compliance with mandates. Requiring COVID-19 immunizations for HCWs, for example, is not a new practice; rather, it is a continuation of a long-standing policy. Vaccination against influenza, hepatitis B, and other infectious diseases has long been mandatory in many health-care settings [38]. Whether to mandate COVID-19 vaccination for HCWs and/or all employees and how to implement such a policy is ultimately a local authority decision. For instance, the local authorities in both New York and California announced a vaccine mandate for state employees [39].

We observed that HCWs' beliefs in infection control measures that have been mandated and optimized during the COVID-19 pandemic namely, universal masking, social distancing, and vaccination as preventive methods for the spread of the Omicron variant or other future variants [40,41] all correlated positively and significantly with their belief in mandatory vaccination for all

eligible adults. They still believed that avoiding unnecessary international travel is an effective measure in preventing the spread of SARS-CoV-2 variants, even after widespread vaccination, perhaps due to the emergence of at least three variants, one of them with high transmissibility and serious clinical morbidity and high mortality (the Delta variant). However, there is a huge consequence of travel ban and lockdown with any emerging variant[42,43].

HCWs who believed that SARS-CoV-2 mutations are expected and will reoccur were significantly less in agreement with the belief that the vaccines are ineffective against the spread of the Omicron variant or other potential future variants, which is an expected and healthy belief, as the best preventive measure to contain the pandemic at present is widespread vaccination This has been observed in HCWs' stringent behavior of abiding by the infection prevention measures, such as universal masking and social distancing, for the same purpose [40,41], which has also been observed in our results, in which agreement with the effectiveness of vaccination to prevent the spread of mutant variants is significantly and positively associated with agreement with mandatory vaccination.

HCWs in critical care areas believed significantly in the ineffectiveness of the vaccines to prevent the spread of mutant variants, including Omicron. This might be explained by the multiple mutations that the Omicron variant has and the critical care workers' anxiety regarding the current vaccine's efficacy against it, being frontliners exposed to severe cases. In the same vein, we observed that HCWs who relied on the WHO as a main source of information disagreed with the vaccine's effectiveness to prevent the spread of the mutant strains, including Omicron, as it is a scientific source that releases only evidence-based information, which has not thus far proven the vaccine's efficacy in that regard.

Male gender was significantly associated with agreement with mandatory vaccination of all eligible adults. This attitude has been observed in multiple studies, as males were more inclined toward vaccine uptake and had much less vaccine hesitancy, while age did not correlate with mandatory vaccination agreement [28,44].

The level of agreement with the effectiveness of vaccines to prevent the spread of mutant variants was significantly associated with agreement with mandatory vaccination, and the same was observed with the level of agreement with the belief that there might be a second national lockdown due to the Omicron variant. This behavior from HCWs—of stringent abidance with vaccination—correlates with their expectation of its effectiveness to prevent the spread of any mutant variant, and their fear of a national lockdown, not unexpectedly, drove them to have an unwavering belief in mandatory vaccination as the best modality to prevent it. However, they did not perceive the effectiveness of unnecessary travel avoidance to be effective in preventing the spread of mutant variants or being superior to mandatory vaccination. Early lockdown and social distancing in the initial phase of the pandemic were useful in slowing the spread of SARS-CoV-2 in Saudi Arabia[45]. In addition, during the peak of the initial lockdown the level of anxiety was associated with being with family members at risk of SARS-CoV-2 infection. Thus, it is understandable that HCWs fear the occurrence of second lockdown with the emergence of the Omicron variant[46].

3.1 Study limitations and strengths

While this research is subject to the limitations of cross-sectional studies, such as sampling, response rate, and uneven geographical representation, the fact that we carried out the study early on in the spread of the Omicron variant also limited our ability to assess the awareness of the HCWs in relation to the variant, especially given the scarce scientific data available after it was first identified. Despite this, the scientific evidence regarding the current vaccines' effectiveness against the Omicron variant will take a significant amount of time to materialize. As with the evolving situation in regard to variants, HCWs' experiences and perceptions are also likely to change. Moreover, HCWs' experiences may differ from one setting to another.

4. Conclusion

432

433

434

435

436

437 438

439 440

441

442

443

444

445446

447

448

449

450 451 This is the first national survey in Saudi Arabia that was conducted in the first week of the WHO Omicron variant announcement, to address HCWs' awareness of the variant, acceptance of vaccine booster doses and agreement with vaccination to prevent the spread of SARS-CoV-2 Omicron variant or future variants. Only about two-thirds of HCWs perceived that vaccination is the best option to prevent the spread of the Omicron variant, indicating the need for future studies to explore the performance of currently available vaccines in terms of the protection they offer against the current variants. At the same time, the HCWs had a strong belief in preventive measures, such as universal masking and social distancing, to prevent the spread of Omicron or future variants, which should still be maintained in practice, at least in healthcare institutions, to prevent nosocomial spread until further evidence can be elucidated.

- 452 Abbreviations:
- 453 **CDC**: Center for Disease Control and Prevention
- 454 **COVID-19**: Coronavirus disease 2019
- 455 **SARS-CoV-2**: Severe acute respiratory syndrome coronavirus 2
- 456 WHO: World Health Organization
- 457 Conflicts of interest: None declared.
- 458 Ethics approval and consent to participate: The study was approved by the institutional review
- board of King Saud University (approval 21/01039/IRB).
- 460 Acknowledgments: This research has been financially supported by Prince Abdullah Ben Khalid
- 461 Celiac Disease Research Chair, under the Vice Deanship of Research Chairs, King Saud University,
- Riyadh, Kingdom of Saudi Arabia. The research team is thankful for the statistical data analysis
- consultation offered by www.hodhodata.com.
- 464 Author contributions: M.H.T., S. Alenezi, M.A., F.A., K.A., F.A., S. Al-Subaie, M.B., Z.M., and J.A.
- conceptualized the study, analyzed the data, and wrote the manuscript. R.A., R.B., F.A., A.
- 466 Alrabiaah, A. Alhaboob, A. Alaraj, N.S.A., R.H., L.A., N.A., A.J., A. Aleyadhy, and W.A. contributed
- 467 to the study design; collected, analyzed, interpreted data; and edited the manuscript.
- All authors reviewed and approved the final version of the manuscript.

470 References

469

World Health Organization, Classification of Omicron (B. 1.1. 529): SARS-CoV-2 variant of concern. *November* **2021**, 26, 2021.

- Volz, E.; Mishra, S.; Chand, M.; Barrett, J.C.; Johnson, R.; Geidelberg, L.; Hinsley, W.R.;
 Laydon, D.J.; Dabrera, G.; O'Toole, Á.; et al. Assessing transmissibility of SARS-CoV-2
 lineage B.1.1.7 in England. *Nature* 2021, 593, 266-269, doi:10.1038/s41586-021-03470-x.
- 476 3. Chen, J.; Wang, R.; Gilby, N.B.; Wei, G.-W. Omicron Variant (B.1.1.529): Infectivity, Vaccine
 477 Breakthrough, and Antibody Resistance. *Journal of Chemical Information and Modeling* **2022**,
 478 62, 412-422, doi:10.1021/acs.jcim.1c01451.
- 4. Al-Tawfiq, J.A.; Hoang, V.T.; Le Bui, N.; Chu, D.T.; Memish, Z.A. The Emergence of the

 Omicron (B.1.1.529) SARS-CoV-2 Variant: What is the Impact on the Continued Pandemic?

 In J Epidemiol Glob Health; 2022; pp. 1-4.
- 482 5. WHO. Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for 483 Member States. Available online:
- https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-tech nical-brief-and-priority-actions-for-member-states (accessed on 25 Dec 2021).
- 486 6. Ren, S.Y.; Wang, W.B.; Gao, R.D.; Zhou, A.M. Omicron variant (B.1.1.529) of SARS-CoV-2:
 487 Mutation, infectivity, transmission, and vaccine resistance. *World J Clin Cases* **2022**, *10*, 1-11,
 488 doi:10.12998/wjcc.v10.i1.1.
- 489 7. Yang, W.; Shaman, J. SARS-CoV-2 transmission dynamics in South Africa and 490 epidemiological characteristics of the Omicron variant. *medRxiv* **2021**, 491 doi:10.1101/2021.12.19.21268073.
- 492 8. TheGuardians. Omicron: everything you need to know about new Covid variant. Available online:
- https://www.theguardian.com/world/2021/nov/26/vaccine-resistant-what-scientists-know-n ew-covid-variant (accessed on 18 Dec 2021).
- 496 9. Torjesen, I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. *Bmj* **2021**, *375*, n2943, doi:10.1136/bmj.n2943.
- 10. Cele, S.; Jackson, L.; Khan, K.; Khoury, D.S.; Moyo-Gwete, T.; Tegally, H.; Scheepers, C.;
 Amoako, D.; Karim, F.; Bernstein, M.; et al. SARS-CoV-2 Omicron has extensive but
 incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for
 infection. *medRxiv* 2021, doi:10.1101/2021.12.08.21267417.
- 502 11. Chen, J.; Wang, R.; Gilby, N.B.; Wei, G.W. Omicron Variant (B.1.1.529): Infectivity, Vaccine
 503 Breakthrough, and Antibody Resistance. *J Chem Inf Model* **2022**, *6*2, 412-422,
 504 doi:10.1021/acs.jcim.1c01451.
- 505 12. Garcia-Beltran, W.F.; St Denis, K.J.; Hoelzemer, A.; Lam, E.C.; Nitido, A.D.; Sheehan, M.L.;
 506 Berrios, C.; Ofoman, O.; Chang, C.C.; Hauser, B.M.; et al. mRNA-based COVID-19 vaccine
 507 boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* 2022, 185,
 508 457-466.e454, doi:10.1016/j.cell.2021.12.033.
- Danza, P.; Koo, T.H.; Haddix, M.; Fisher, R.; Traub, E.; K, O.Y.; Balter, S. SARS-CoV-2
 Infection and Hospitalization Among Adults Aged ≥18 Years, by Vaccination Status, Before
 and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance Los Angeles County,
 California, November 7, 2021-January 8, 2022. MMWR Morb Mortal Wkly Rep 2022, 71,
- 513 177-181, doi:10.15585/mmwr.mm7105e1.

- 514 14. Al-Tawfiq, J.A.; Al-Yami, S.S.; Rigamonti, D. Changes in healthcare managing COVID and
 515 non-COVID-19 patients during the pandemic: striking the balance. *Diagn Microbiol Infect Dis*516 **2020**, 98, 115147, doi:10.1016/j.diagmicrobio.2020.115147.
- 517 15. Rigamonti, D.; Leonardi, R.; Al-Tawfiq, J.A. Coronavirus Disease Mortality: Understanding 518 Regional Differences. *Erciyes Medical Journal* **2022**, 3-7.
- Temsah, M.H.; Al Huzaimi, A.; Alrabiaah, A.; Alamro, N.; Al-Sohime, F.; Al-Eyadhy, A.;
 Alhasan, K.; Kari, J.A.; Alhaboob, A.; Alsalmi, A.; et al. Changes in healthcare workers'
 knowledge, attitudes, practices, and stress during the COVID-19 pandemic. *Medicine*(Baltimore) 2021, 100, e25825, doi:10.1097/md.0000000000025825.
- 17. Lasalvia, A.; Bodini, L.; Amaddeo, F.; Porru, S.; Carta, A.; Poli, R.; Bonetto, C. The Sustained Psychological Impact of the COVID-19 Pandemic on Health Care Workers One Year after the Outbreak-A Repeated Cross-Sectional Survey in a Tertiary Hospital of North-East Italy
- the Outbreak-A Repeated Cross-Sectional Survey in a Tertiary Hospital of North-East Italy. *Int J Environ Res Public Health* **2021**, *18*, doi:10.3390/ijerph182413374.
- Mohapatra, R.K.; Tiwari, R.; Sarangi, A.K.; Islam, D.R.; Chakraborty, C.; Dhama, K.
 COMMENTARYOmicron (B.1.1.529) variant of SARS-CoV-2- Concerns, challenges and
 recent updates. *J Med Virol* 2022, doi:10.1002/jmv.27633.
- Khandia, R.; Singhal, S.; Alqahtani, T.; Kamal, M.A.; El-Shall, N.A.; Nainu, F.; Desingu, P.A.;
 Dhama, K. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high
 global health concerns and strategies to counter it amid ongoing COVID-19 pandemic.
 Environ Res 2022, 209, 112816, doi:10.1016/j.envres.2022.112816.
- 534 20. SPA. Health Ministry: Detecting Omicron Variant Case of Coronavirus in Saudi Arabia for
 535 Citizen Coming Back from North African Country. Available online:
 536 www.spa.gov.sa/2308747 (accessed on
- Temsah, M.-H.; Alenezi, S.; Alarabi, M.; Aljamaan, F.; Alhasan, K.; Assiri, R.; Bassrawi, R.;
 Alshahrani, F.; Alhaboob, A.; Alaraj, A.; Alharbi, N.S.; Alrabiaah, A.; Halwani, R.; Jamal, A.;
 Abdulmajeed, N.; Alfarra, L.; Almashdali, W.; Al-Eyadhy, A.; AlZamil, F.; Alsubaie, S.;
 Barry, M.; Memish, Z.A.; Al-Tawfiq, J.A. Healthcare Workers' SARS-CoV-2 Omicron Variant
 Uncertainty-Related Stress, Resilience, and Coping Strategies during the First Week of the
 World Health Organization's Alert. Int. J. Environ. Res. Public Health 2022, 19, 1944.
 https://doi.org/10.3390/ijerph19041944
- Temsah, M.H.; Alhuzaimi, A.N.; Alamro, N.; Alrabiaah, A.; Al-Sohime, F.; Alhasan, K.; Kari, J.A.; Almaghlouth, I.; Aljamaan, F.; Al Amri, M.; et al. Knowledge, Attitudes, and Practices of Healthcare Workers During the Early COVID-19 Pandemic in a Main, Academic Tertiary Care Centre in Saudi Arabia. *Epidemiol Infect* **2020**, 1-29, doi:10.1017/S0950268820001958.
- Temsah, M.H.; Al-Sohime, F.; Alamro, N.; Al-Eyadhy, A.; Al-Hasan, K.; Jamal, A.;
 Al-Maglouth, I.; Aljamaan, F.; Al Amri, M.; Barry, M.; et al. The psychological impact of
 COVID-19 pandemic on health care workers in a MERS-CoV endemic country. *J Infect Public Health* **2020**, *13*, 877-882, doi:10.1016/j.jiph.2020.05.021.
- Barry, M.; Temsah, M.H.; Aljamaan, F.; Saddik, B.; Al-Eyadhy, A.; Alenezi, S.; Alamro, N.;
 Alhuzaimi, A.N.; Alhaboob, A.; Alhasan, K.; et al. COVID-19 vaccine uptake among
 healthcare workers in the fourth country to authorize BNT162b2 during the first month of
 rollout. *Vaccine* **2021**, doi:10.1016/j.vaccine.2021.08.083.

- 556 25. Temsah, M.H.; Barry, M.; Aljamaan, F.; Alhuzaimi, A.N.; Al-Eyadhy, A.; Saddik, B.;
- Alsohime, F.; Alhaboob, A.; Alhasan, K.; Alaraj, A.; et al. SARS-CoV-2 B.1.1.7 UK Variant of
- 558 Concern Lineage-Related Perceptions, COVID-19 Vaccine Acceptance and Travel Worry
- Among Healthcare Workers. Front Public Health 2021, 9, 686958,
- doi:10.3389/fpubh.2021.686958.
- Rabinowitz, L.G.; Rabinowitz, D.G. Women on the Frontline: A Changed Workforce and the Fight Against COVID-19. *Acad Med* **2021**, *96*, 808-812, doi:10.1097/acm.00000000000000011.
- 563 27. Alhasan, K.; Aljamaan, F.; Temsah, M.H.; Alshahrani, F.; Bassrawi, R.; Alhaboob, A.; Assiri,
- 564 R.; Alenezi, S.; Alaraj, A.; Alhomoudi, R.I.; et al. COVID-19 Delta Variant: Perceptions,
- Worries, and Vaccine-Booster Acceptability among Healthcare Workers. Healthcare (Basel)
- 566 **2021**, 9, doi:10.3390/healthcare9111566.
- 567 28. Al-Sanafi, M.; Sallam, M. Psychological Determinants of COVID-19 Vaccine Acceptance
- among Healthcare Workers in Kuwait: A Cross-Sectional Study Using the 5C and Vaccine
- 569 Conspiracy Beliefs Scales. Vaccines (Basel) 2021, 9, doi:10.3390/vaccines9070701.
- 570 29. Karim, S.S.A.; Karim, Q.A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19
- pandemic. Lancet 2021, 398, 2126-2128, doi:10.1016/s0140-6736(21)02758-6.
- 572 30. Araf, Y.; Akter, F.; Tang, Y.D.; Fatemi, R.; Parvez, M.S.A.; Zheng, C.; Hossain, M.G. Omicron
- variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19
- vaccines. J Med Virol 2022, doi:10.1002/jmv.27588.
- 575 31. Cele, S.; Jackson, L.; Khoury, D.S.; Khan, K.; Moyo-Gwete, T.; Tegally, H.; San, J.E.; Cromer,
- D.; Scheepers, C.; Amoako, D.G.; et al. Omicron extensively but incompletely escapes Pfizer
- 577 BNT162b2 neutralization. *Nature* **2021**, doi:10.1038/s41586-021-04387-1.
- 578 32. Greaney, A.J.; Starr, T.N.; Gilchuk, P.; Zost, S.J.; Binshtein, E.; Loes, A.N.; Hilton, S.K.;
- 579 Huddleston, J.; Eguia, R.; Crawford, K.H.D.; et al. Complete Mapping of Mutations to the
- 580 SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition. Cell Host
- 581 *Microbe* **2021**, 29, 44-57.e49, doi:10.1016/j.chom.2020.11.007.
- 582 33. Ferré, V.M.; Peiffer-Smadja, N.; Visseaux, B.; Descamps, D.; Ghosn, J.; Charpentier, C.
- Omicron SARS-CoV-2 variant: What we know and what we don't. Anaesth Crit Care Pain
- 584 *Med* **2021**, 41, 100998, doi:10.1016/j.accpm.2021.100998.
- 585 34. Barry, M.; Temsah, M.H.; Alhuzaimi, A.; Alamro, N.; Al-Eyadhy, A.; Aljamaan, F.; Saddik,
- 586 B.; Alhaboob, A.; Alsohime, F.; Alhasan, K.; et al. COVID-19 vaccine confidence and
- hesitancy among health care workers: A cross-sectional survey from a MERS-CoV
- experienced nation. *PLoS One* **2021**, *16*, e0244415, doi:10.1371/journal.pone.0244415.
- 589 35. Li, M.; Luo, Y.; Watson, R.; Zheng, Y.; Ren, J.; Tang, J.; Chen, Y. Healthcare workers' (HCWs)
- 590 attitudes and related factors towards COVID-19 vaccination: a rapid systematic review.
- 591 Postgrad Med J **2021**, doi:10.1136/postgradmedj-2021-140195.
- 592 36. EEOC. EEOC Issues Updated COVID-19 Technical Assistance. Available online:
- 593 <u>https://www.eeoc.gov/newsroom/eeoc-issues-updated-covid-19-technical-assistance</u>
- 594 (accessed on 27 Dec 2021).
- 595 37. Weber, D.J.; Al-Tawfiq, J.A.; Babcock, H.M.; Bryant, K.; Drees, M.; Elshaboury, R.; Essick, K.;
- Fakih, M.; Henderson, D.K.; Javaid, W.; et al. Multisociety statement on coronavirus disease
- 597 2019 (COVID-19) vaccination as a condition of employment for healthcare personnel. *Infect*
- 598 *Control Hosp Epidemiol* **2021**, 1-9, doi:10.1017/ice.2021.322.

- 599 38. Klompas, M.; Pearson, M.; Morris, C. The Case for Mandating COVID-19 Vaccines for Health Care Workers. *Ann Intern Med* **2021**, *174*, 1305-1307, doi:10.7326/m21-2366.
- 601 39. Olick, R.S.; Shaw, J.; Yang, Y.T. Ethical Issues in Mandating COVID-19 Vaccination for 602 Health Care Personnel. *Mayo Clin Proc* **2021**, *96*, 2958-2962, doi:10.1016/j.mayocp.2021.10.020.
- 40. Al-Metwali, B.Z.; Al-Jumaili, A.A.; Al-Alag, Z.A.; Sorofman, B. Exploring the acceptance of COVID-19 vaccine among healthcare workers and general population using health belief model. *J Eval Clin Pract* **2021**, *27*, 1112-1122, doi:10.1111/jep.13581.
- O'Donohue, L.S.; Fletcher-Gutowski, S.; Sidhu, A.; Verma, A.; Phillips, T.C.; Misra, P.G.
 Mask use among health care workers and feelings of safety at work pre- and post COVID-19 vaccine. *Am J Infect Control* 2021, doi:10.1016/j.ajic.2021.11.009.
- 609 42. Singhal, T. The Emergence of Omicron: Challenging Times Are Here Again! *Indian J Pediatr* 610 **2022**, 1-7, doi:10.1007/s12098-022-04077-4.
- Mallapaty, S. Omicron-variant border bans ignore the evidence, say scientists. In *Nature*; England, 2021; Volume 600, p. 199.
- Maraqa, B.; Nazzal, Z.; Rabi, R.; Sarhan, N.; Al-Shakhra, K.; Al-Kaila, M. COVID-19 vaccine
 hesitancy among health care workers in Palestine: A call for action. *Prev Med* 2021, 149,
 106618, doi:10.1016/j.ypmed.2021.106618.
- Ahmad Alajlan, S.; Alhusseini, N.K.; Mohammed Basheeruddin Asdaq, S.; Mohzari, Y.;
 Alamer, A.; Alrashed, A.A.; Alamri, A.S.; Alsanie, W.F.; Alhomrani, M. The impact of lockdown strategies on the basic reproductive number of coronavirus (COVID-19) cases in
 Saudi Arabia. Saudi J Biol Sci 2021, 28, 4926-4930, doi:10.1016/j.sjbs.2021.06.047.
- 46. Albagmi, F.M.; AlNujaidi, H.Y.; Al Shawan, D.S. Anxiety Levels Amid the COVID-19
 Lockdown in Saudi Arabia. *Int J Gen Med* 2021, 14, 2161-2170, doi:10.2147/ijgm.s312465.